Management of Renal Insufficiency with Elevated Creatinine

Evaluation of Renal Function

The American Diabetes Association recommends that renal insufficiency be diagnosed by the presence of persistently elevated serum creatinine, reduced estimated glomerular filtration rate (eGFR), or other manifestations of renal damage 1, 2
The eGFR should be calculated using validated formulas such as the CKD-EPI equation (preferred), MDRD, or Cockcroft-Gault, which take into account age, sex, ethnicity, and serum creatinine 3, 1
An eGFR <60 mL/min/1.73 m² indicates chronic kidney disease stage 3, while values <30 and <15 mL/min/1.73 m² indicate stages 4 and 5, respectively 3
Albuminuria should be evaluated by the urine albumin-to-creatinine ratio (UACR) on a spot urine sample 3, 1

Normal UACR: <30 mg/g of creatinine 1
Moderately elevated albuminuria: 30-299 mg/g of creatinine 1
Severely elevated albuminuria: ≥300 mg/g of creatinine 1
Due to biological variability >20% between urine albumin excretion measurements, two out of three samples collected over a period of 3 to 6 months must be abnormal before considering a patient to have elevated albuminuria 1

Optimizing blood pressure control is essential to reduce the risk or slow the progression of renal insufficiency 1, 2, 4
Reducing blood pressure variability is also important to slow the progression of chronic kidney disease 4, 1

For hypertensive patients with moderately elevated UACR (30-299 mg/g), an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (ARA) is recommended 5, 1
These medications are strongly recommended for patients with UACR ≥300 mg/g and/or eGFR <60 mL/min/1.73 m² 5, 1
Treatment with ACEI or ARA should not be discontinued due to minor increases in serum creatinine (≤30%) in the absence of volume depletion 4, 1

For individuals with chronic kidney disease stage 3 or higher not on dialysis, dietary protein intake should be limited to 0.8 g/kg body weight per day (recommended daily intake) 6, 1
For patients on dialysis, higher levels of dietary protein intake should be considered, as malnutrition is a major issue in some dialysis patients 6, 1

Patients should be referred to a nephrologist for evaluation if they have an eGFR <30 mL/min/1.73 m² 1
Rapid referral to a nephrologist is justified in cases of uncertainty about the etiology of kidney disease, difficult management issues, and rapidly progressive kidney disease 1

The American College of Cardiology and Circulation recommend excluding nephrotoxic drug exposure, such as NSAIDs, aminoglycosides, and contrast media, in patients with suspected chronic kidney disease 7, 8

The Journal of the American College of Cardiology and Circulation suggest checking creatinine and potassium within 3 days and at 1 week after initiation of ACE inhibitor or ARB therapy, then monthly for the first 3 months, to monitor for potential adverse effects 8, 9
The American College of Cardiology recommends avoiding NSAIDs and COX-2 inhibitors completely in patients with chronic kidney disease, as they may worsen kidney function 8, 9

The American College of Cardiology and Circulation recommend immediate nephrology referral or hospitalization if serum potassium >5.5 mEq/L, as this indicates a high risk of hyperkalemia 8, 9
The Hepatology journal recommends urgent action if signs of volume overload, such as pulmonary edema or severe hypertension, are present, as these can indicate acute kidney injury 7